Fda authorizes lower 1,200 mg intravenous and subcutaneous dose of regen-cov™ (casirivimab and imdevimab) antibody cocktail to treat patients with covid-19

Tarrytown, n.y., june 4, 2021 /prnewswire/ --  eua supported by pivotal phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% only antibody therapy currently available in all 50 states, including eight states with high rates of two variants of concern regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the u.s. food and drug administration (fda) updated the emergency use authorization (eua) for regen-cov™, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab), which is half the dose originally authorized.
REGN Ratings Summary
REGN Quant Ranking